Your request to link to rcsb for Procathepsin L

---

• 1CJL: crystal structure of a cysteine protease proform
• 1CS8: crystal structure of procathepsin l
• 1ICF: crystal structure of mhc class ii associated p41 ii fragment in complex with cathepsin l (10.1093/EMBOJ/18.4.793 )
• 1MHW: design of non-covalent inhibitors of human cathepsin l. from the 96- residue proregion to optimized tripeptides (10.1021/JM020238T )
• 2NQD: crystal structure of cysteine protease inhibitor, chagasin, in complex with human cathepsin l (10.1016/J.JMB.2007.05.005 )
• 2VHS: cathsilicatein, a chimera (10.1039/B718264C )
• 2XU1: cathepsin l with a nitrile inhibitor (10.1002/ANIE.201006781 )
• 2XU3: cathepsin l with a nitrile inhibitor (10.1002/ANIE.201006781 )
• 2XU4: cathepsin l with a nitrile inhibitor (10.1002/ANIE.201006781 )
• 2XU5: cathepsin l with a nitrile inhibitor (10.1002/ANIE.201006781 )
• 2YJ2: cathepsin l with a nitrile inhibitor (10.1002/CMDC.201100353 )
• 2YJ8: cathepsin l with a nitrile inhibitor (10.1002/CMDC.201100353 )
• 2YJ9: cathepsin l with a nitrile inhibitor (10.1002/CMDC.201100353 )
• 2YJB: cathepsin l with a nitrile inhibitor (10.1002/CMDC.201100353 )
• 2YJC: cathepsin l with a nitrile inhibitor (10.1002/CMDC.201100353 )
• 3BC3: exploring inhibitor binding at the s subsites of cathepsin l (10.1021/JM701190V )
• 3H89: a combined crystallographic and molecular dynamics study of cathepsin- l retro-binding inhibitors(compound 4) (10.1021/JM900596Y )
• 3H8B: a combined crystallographic and molecular dynamics study of cathepsin- l retro-binding inhibitors(compound 9) (10.1021/JM900596Y )
• 3H8C: a combined crystallographic and molecular dynamics study of cathepsin- l retro-binding inhibitors (compound 14) (10.1021/JM900596Y )
• 3HHA: crystal structure of cathepsin l in complex with az12878478 (10.1016/J.BMCL.2009.05.071 )
• 3HWN: cathepsin l with az13010160 (10.1016/J.BMCL.2009.06.090 )
• 3IV2: crystal structure of mature apo-cathepsin l c25a mutant (10.1038/NCOMMS1204 )
• 3K24: crystal structure of mature apo-cathepsin l c25a mutant in complex with gln-leu-ala peptide (10.1038/NCOMMS1204 )
• 3KSE: unreduced cathepsin l in complex with stefin a
• 3OF8: structural basis for reversible and irreversible inhibition of human cathepsin l by their respective dipeptidyl glyoxal and diazomethylketone inhibitors (10.1016/J.JSB.2010.09.007 )
• 3OF9: structural basis for irreversible inhibition of human cathepsin l by a diazomethylketone inhibitor (10.1016/J.JSB.2010.09.007 )
• 4AXL: human cathepsin l apo form with zn (10.1002/CMDC.201300112 )
• 4AXM: triazine cathepsin inhibitor complex (10.1002/CMDC.201300112 )
• 5F02: cathepsin l in complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide (10.1021/ACS.JMEDCHEM.5B01875 )
• 5I4H: caught in the act: the crystal structure of cleaved cathepsin l bound to the active site of cathepsin l (10.1002/1873-3468.12140 )
• 5MAE: cathepsin l in complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide (10.1002/CMDC.201600563 )
• 5MAJ: cathepsin l in complex with 4-[cyclopentyl(imidazo[1,2-a]pyridin-2- ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile (10.1002/CMDC.201600563 )
• 5MQY: cathepsin l in complex with 4-[1,3-benzodioxol-5-ylmethyl(2- phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile (10.1021/ACS.JMEDCHEM.6B01881 )
• 6EZP: cathepsin l in complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)- 5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9, 14,18(22),19-heptaene-3-carboxamide (10.1021/ACS.JMEDCHEM.7B01869 )
• 6EZX: cathepsin l in complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)- 5-oxo-17-oxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14, 18(22),19-heptaene-3-carboxamide (10.1021/ACS.JMEDCHEM.7B01869 )
• 6F06: cathepsin l in complex with (3s,14e)-8-(azetidin-3-yl)-19-chloro-n-(1- cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06, 11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide (10.1021/ACS.JMEDCHEM.7B01869 )
• 6JD0: structure of mutant human cathepsin l, engineered for gag binding
• 6JD8: structure of a proline specific mutant of human cathepsin l